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Abstract: 
The human cervicovaginal microbiome has an important role in the health and homoeostasis 
of the female reproductive tract. A eubiotic microbiome is typically dominated with lactic acid 
producing bacteria and is categorised into five community state types. Issues arise when the 
microbiome becomes dysbiotic, with the microbial composition shifting to contain a greater 
relative abundance of strict and facultative anaerobes. This shift will lead to several adverse 
changes in the vaginal environment including compromised epithelial cells, cell death, 
inflammation, and greater susceptibility to infection. These changes are associated with 
various adverse outcomes including infections, preterm birth, and infertility. In this review, we 
discuss how the cervicovaginal microbiome influences these outcomes and possible future 
directions of treatment and research. 





The human microbiome is a unique collection of microorganisms which colonises the body 
and has an important role in health and homeostasis. The cervicovaginal microbiome is 
particularly distinctive as it is frequently dominated by Lactobacillus with decreased diversity 
of other bacteria, unlike what is seen in other sites such as the gut1. The cervicovaginal 
microbiome is extremely important to the host tissue as it maintains an acidic environment, 
preventing pathogenic colonisation, and modulates inflammation by cross-kingdom 
signalling1. Thus, the composition of cervicovaginal microbiome plays an important role in 
health outcomes for women particularly in relation to vaginal infection, pregnancy, and fertility. 
 
The Eubiotic Microbiome: 
 
Early culture-based studies identified Lactobacillus as the dominant bacteria in the vaginal 
microbiome and recognised that it may play a key role in maintaining the health of the female 
reproductive tract2. Molecular-based techniques, including relatively recent next generation 
sequencing, have been used to obtain an in-depth understanding of vaginal flora and to 
classify microbiota into broad profiles termed community state types (CST)3, 4. Four CSTs are 
dominated by a species of Lactobacillus; Lactobacillus crispatus (CST I), L. gasseri (CST II), 
L. iners (CST III) and L. jensenii (CST V). CST IV is characterised by various strict and 
facultative anaerobes and is typified by the absence of a dominant Lactobacillus species. The 
CSTs have varying levels of stability and transitions between CSTs are associated with 
composition, menstrual cycle, and sexual activity4. Lactobacillus produces lactic acid, 
maintaining vaginal pH at ≤4.5, promoting a selective environment for acid tolerant bacteria 
whilst suppressing pathogenic colonisation (Figure 1). Lactic acid has an immunomodulatory 
function, acting directly on epithelial cells to promote an anti-inflammatory response via the 
production of interleukin(IL)-1 receptor antagonist, as well as promoting the production of pro-




Figure 1. Eubiotic microbiome. Bacteria maintain the mucosal layer, release antimicrobial 
peptides, and lactic acid. Lactic acid lowers the pH, preventing pathogenic colonisation, and 
modulating the immune response, protecting the epithelial layer. Created with BioRender.com.  
  
 
The Dysbiotic Microbiome: 
 
Dysbiosis is defined as a change in microbiota composition relative to the community of 
commensal bacteria seen in a healthy state6. There is no specific bacteria universally seen in 
dysbiosis but it is frequently associated with increased relative abundance of Gardnerella, 
Prevotella, and Atopbium7, 8. This shift in composition results in a decrease in lactic acid, with 
an increase in short chain fatty acids, amines, and pH (Figure 2)9. Dysbiosis is also associated 
with several detrimental changes in the cervicovaginal environment including alterations in the 
cytoskeleton, increased cell death, an imbalance in the concentration of antimicrobial peptides 
and increased production of pro-inflammatory cytokines (Figure 2)10. These changes are 





Figure 2. Dysbiotic microbiome. There is a breakdown in the mucosal layer, and the 
production of amines and short chain fatty acids, increasing the pH. This creates an 
environment selective for strict and facultative anaerobes, a pro-inflammatory response in the 





Bacterial vaginosis (BV) is the most common vaginal infection, characterised by dysbiosis and 
the associated metabolomic changes. BV often is asymptomatic, but women may experience 
symptoms such as discoloured vaginal discharge, and a ‘fishy’ odour. The prevalence of BV 
is variable between different populations but worldwide prevalence is approximately 30%, with 
prevalence in Australia considerably lower at 4.7%11. Treatment with oral or intravaginal 
antibiotics is only recommend for women experiencing symptoms. However, after treatment, 
reoccurrence is common with up to 60-80% of women experiencing reoccurrence within 12-
months after treatment12. Recent research has now shifted to investigating the variables 
associated with reoccurrence, specifically microbiota composition, to improve the treatment 
outcomes for women with BV13.  
 
Sexually Transmitted Infections 
 
Dysbiosis of the cervicovaginal microbiota is known to increase the risk of acquiring a sexually 
transmitted infection (STI). Numerous longitudinal studies have determined that high 
microbiota diversity increases the risk of acquiring an infection14. A possible mechanism which 
increases susceptibility may be an inflammatory response to diverse bacteria. Gosmann et 
al.15 investigated the association between the microbiome, inflammation, and human 
immunodeficiency virus (HIV)-acquisition in a prospective cohort study of South Africa women. 
They determined that women with polymicrobial microbiomes dominated with anaerobes, had 
increased activated mucosal CD4+ T cells, and 4-fold greater risk of HIV infection. They 
suggested that the target cells were responding to the microbial diversity, which in turn 
increase host susceptibility15. A similar response is also hypothesised to be involved in human 
papillomavirus infection, but is yet to be investigated16. Another mechanism involved in the 
susceptibility is the modulation of cellular functions. Ceccarani et al.17 investigated the 
changes in the microbiome and metabolome during Chlamydia infection. In comparison to a 
healthy state, they showed clear changes in composition occurred during infection, specifically 
a decrease in lactic acid. Similarly, Edwards et al.18 showed D (-) lactic acid produced by the 
microbiome may prevent cellular proliferation, protecting against Chlamydia infection. They 
suggested that a eubiotic microbiome modulates cell function preventing Chlamydia infection 
in vitro. These studies support that via direct metabolic profiles and cross talk involved in host 




The composition of the cervicovaginal microbiome has been associated with increased risk of 
adverse outcomes in pregnancy such as preterm birth. Preterm birth is defined as either a live 
or still birth after 20 weeks’ gestation but before 37 weeks19. During pregnancy, hormonal 
changes alters the composition of the cervicovaginal microbiota resulting in an increased 
abundance of Lactobacillus. Several studies have shown that women with a diverse, non-
Lactobacillus dominated microbiome are at a greater risk of preterm birth20, 21. However, there 
is no defined profile of bacteria associated with adverse outcomes and results from each study 
greatly vary due to the population and study design. Kosti et al.22 recently conducted meta-
analysis to address these issues and created a microbial signature associated with preterm 
birth. They successfully identified a lack of Lactobacillus as a predictor of preterm birth, 
alongside several species which had been previously reported. Interestingly, they identified 
an association between preterm birth and the presence of Olsenella and Clostridium sensu 
stricto which had not been previously reported 22. Overall these promising results show the 
potential for novel diagnostics that could guide interventions to improve pregnancy outcomes 




Infertility is defined as the inability to attain a clinical pregnancy after 12 months of regular 
unprotected intercourse 19. In vitro fertilisation (IVF) is now the most common procedure used 
to treat a range of infertility issues 23. However, in Australia, the success rate of IVF procedures 
is reported as approximately 30% with little improvement over the last five years 24. Poor 
outcomes of IVF  have been associated with the composition of the cervicovaginal microbiome 
in several studies, although these studies often have a small sample size and mixed quality 
of methodologies. Initially Hyman et al.20 associated diverse vaginal bacteria with poor IVF 
outcomes and suggested that the composition of the microbiome at the time of embryo transfer 
may be an important factor in the success of IVF treatment. Since this initial study there have 
been several others that have associated increased diversity of cervicovaginal microbiota and 
the presence of specific bacteria, with IVF failure25-27. However, there is no defined profile of 
microbiota associated with poor outcomes in IVF treatment, mostly due to the lack of larger 
studies. To understand the pathogenesis of this relationship, Fu et al.28 conducted a study to 
assess changes in the microbiome and metabolome in association with the outcomes of IVF 
failure. They determined that there was a lack of key metabolites necessary for embryo 
development and implantation such as glycerophospholipids and benzopyran in those who 
experienced IVF failure, and in turn these metabolite differences were associated with different 
compositions of microbiota. Whilst this study shows some promising results, the 




It is clear the cervicovaginal microbiome plays a key role in health outcomes for women, with 
dysbiosis commonly observed in a range of adverse events. However, the mechanisms 
underlying these relationships are not well understood. Future microbiome and metabolome 
models will provide a method of representing these interactions in vitro. Delgado-Diaz et al.29, 
used key metabolites associated with a Lactobacillus dominated microbiome and BV-
associated microbiome to model the response of cells. This showed the immunomodulatory 
effect of lactic acid, but also showed that a lack of lactic acid and high concentrations of short 
chain fatty acids would stimulate increased production of pro-inflammatory cytokines. Thus, 
the approach of using an in vitro model is a promising method to better understand the 
microbiome and host cell interplay at a molecular level. Furthermore, large studies are 
necessary to determine predictive biomarkers of adverse outcomes, and to inform 
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